Dr. Matthew N. Meriggioli is Assistant Professor and director of the Neuromuscular Disorders Section in the Department of Neurology and Rehabilitation Medicine, University of Illinois, Chicago. He also is the program director for the clinical neurophysiology and neuromuscular medicine fellowship programs. He is board certified in Neurology with added qualifications in Neuromuscular Medicine and Clinical Neurophysiology.
Carolina.Dr Meriggioli received his medical degree from the Rosalind Franklin University of Medicine and Science/ the Chicago Medical School. He completed an internal medicine internship at Northwestern University Medical Center, and a neurology residency at Loyola and Hines Veteran’s Administration Hospital in Illinois. He then completed a 2-year neuromuscular fellowship at Duke University Medical Center in Durham, North Carolina.
Dr. Meriggioli maintains a primary clinical interest in the diagnosis and management of patients with neuromuscular disease, particularly myasthenia gravis (MG). He has been caring for patients with (MG) since 1996. He has been an investigator in a number of MG clinical trials, including investigations involving mycophenolate mofetil (CellCept), etanercept, and the investigation of the clinical efficacy of thymectomy in patients with MG. In addition to his clinical activities, he is involved in ongoing basic research, funded by the National Institutes of Health and the Muscular Dystrophy Association (MDA) exploring the immune regulation of experimental MG.
Among his publications - which include more than 50 scientific papers, abstracts and reviews – he is the coauthor of the textbook Neuromuscular Junction Disorders: Diagnosis and Treatment (Marcel Dekker, 2004). Dr. Meriggioli lectures frequently on the diagnosis, treatment, and pathogenesis of neuromuscular diseases, including MG. He has been a member of the Medical and Scientific Advisory Board of the Myasthenia Gravis Foundation of America (MGFA) since 1998, and is currently chair of the MGFA research and grants committee.
· Sheng JR, Li L, Prabhakar BS, Meriggioli MN. Acetylcholine receptor-α subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve 2009;40:279-286.
· Meriggioli MN, Sanders DB. Myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8(5):475-90.
· Meriggioli MN. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci. 2009;26:94-108.
· Li L, Sheng JR, Mulherkar N, Prabhakar BS, Meriggioli MN. Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene. Cancer Res 2008;68(18):7352-61.
· Mullins LL, Carpentier MY, Paul RH, Sanders DB, Muscle Study Group. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 2008; 38(2):947-56. (Role: Co-author, investigator)
· Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957-63. (Role: Co-author, investigator)
· Sheng JR, Li L, Ganesh BB, Prabhakar BS, Meriggioli MN. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia. Clin Immunol 2008;128(2):172-180.
· The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-399. (Role: Co-author, investigator, planning of the study, drafting of the manuscript).
· Wolfe GI, Barohn RJ, Sanders DB, McDermott MP, and the Muscle Study Group. Comparison of outcome measures from a trial of mycophenolate in myasthenia gravis. Muscle Nerve 2008;38(5):1429-1433. (Role: Co-author, Site investigator)
· Meriggioli MN, Sheng JR, Li L, Prabhakar BS. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann NY Acad Sci 2008;1132:276-282.
· Sheng JR, Li LC, Ganesh BB, Vasu C, Prabhakar BS, Meriggioli MN. Suppression of experimental autoimmune myasthenia gravis (EAMG) by Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is associated with an expansion of FoxP3+ regulatory T cells. J Immunol 2006 Oct 15;177(8):5296-306.
· Rowin J, Cheng G, Lewis SL, Meriggioli MN. Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve 2006 Nov;34(5):666-9.
· Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006;66:1245-1247.
· Tüzün E, Saini SS, Ghosh S, Rowin J, Meriggioli MN, Christadoss P. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromusc Disord 2006;16(2):137-43.
· Meriggioli MN. IVIG in myasthenia gravis: getting enough “bang for the buck”. Neurology 2007;68:803-804.
· Sheng JR, Li LC, Ganesh BB, Vasu C, Prabhakar BS, Meriggioli MN. Suppression of experimental autoimmune myasthenia gravis (EAMG) by Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is associated with an expansion of FoxP3+ regulatory T cells. J Immunol 2006 Oct 15;177(8):5296-306.
· Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006;66:1245-1247.
· Tüzün E, Saini SS, Ghosh S, Rowin J, Meriggioli MN, Christadoss P. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromusc Disord 2006;16(2):137-43.